Abstract
Rho proteins belong to the Ras superfamily of small GTPases and function as binary switches that shuttle between active and inactive states based on the nature of bound guanine nucleotide. Three sets of regulatory proteins, namely, guanine dissociation inhibitors, guanine exchange factors, and GTPase activating proteins (GAPs) control the balance between active and inactive Rho proteins. There are more than 70 RhoGAPs encoded in the human genome. The RhoGAP family is distinguished by the presence of the RhoGAP domain. However, the majority of RhoGAPs contain multiple additional domains. There are as many as eight domains in some of these proteins. The modular structure of GAPs is important for their interaction with other proteins. A significant number of RhoGAPs have been shown to be present in altered abundance in a variety of human cancers or cell lines. The ability of RhoGAPs to modulate Rho mediated signaling pathways may lend themselves as targets for small molecule therapeutic agents against cancer.
Keywords: Rho, RhoGAP, signal transduction, GTPase activating proteins, transformation, invasion, metastasis, cytoskeleton, interacting proteins, drug targets
Current Protein & Peptide Science
Title: Rho GTPase Activating Proteins in Cancer Phenotypes
Volume: 7 Issue: 4
Author(s): Raj P. Kandpal
Affiliation:
Keywords: Rho, RhoGAP, signal transduction, GTPase activating proteins, transformation, invasion, metastasis, cytoskeleton, interacting proteins, drug targets
Abstract: Rho proteins belong to the Ras superfamily of small GTPases and function as binary switches that shuttle between active and inactive states based on the nature of bound guanine nucleotide. Three sets of regulatory proteins, namely, guanine dissociation inhibitors, guanine exchange factors, and GTPase activating proteins (GAPs) control the balance between active and inactive Rho proteins. There are more than 70 RhoGAPs encoded in the human genome. The RhoGAP family is distinguished by the presence of the RhoGAP domain. However, the majority of RhoGAPs contain multiple additional domains. There are as many as eight domains in some of these proteins. The modular structure of GAPs is important for their interaction with other proteins. A significant number of RhoGAPs have been shown to be present in altered abundance in a variety of human cancers or cell lines. The ability of RhoGAPs to modulate Rho mediated signaling pathways may lend themselves as targets for small molecule therapeutic agents against cancer.
Export Options
About this article
Cite this article as:
P. Kandpal Raj, Rho GTPase Activating Proteins in Cancer Phenotypes, Current Protein & Peptide Science 2006; 7 (4) . https://dx.doi.org/10.2174/138920306778018025
DOI https://dx.doi.org/10.2174/138920306778018025 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice
Current Molecular Medicine Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Advanced Platelet-Rich Fibrin Extract Treatment Promotes the Proliferation and Differentiation of Human Adipose-Derived Mesenchymal Stem Cells through Activation of Tryptophan Metabolism
Current Stem Cell Research & Therapy Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Glioblastoma Targeted Gene Therapy Based on pEGFP/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles
Current Gene Therapy The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Stem Cell Regenerative Potential Combined with Nanotechnology and Tissue Engineering for Myocardial Regeneration
Current Stem Cell Research & Therapy Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme
Current Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design